Literature DB >> 17761758

Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies.

Roberta Morosetti1, Massimiliano Mirabella, Carla Gliubizzi, Aldobrando Broccolini, Cristina Sancricca, Mario Pescatori, Teresa Gidaro, Giorgio Tasca, Roberto Frusciante, Pietro Attilio Tonali, Giulio Cossu, Enzo Ricci.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is the third most frequent inherited muscle disease. Because in FSHD patients the coexistence of affected and unaffected muscles is common, myoblasts expanded from unaffected FSHD muscles have been proposed as suitable tools for autologous cell transplantation. Mesoangioblasts are a new class of adult stem cells of mesodermal origin, potentially useful for the treatment of primitive myopathies of different etiology. Here, we report the isolation and characterization of mesoangioblasts from FSHD muscle biopsies and describe morphology, proliferation, and differentiation abilities of both mesoangioblasts and myoblasts derived from various affected and unaffected muscles of nine representative FSHD patients. We demonstrate that mesoangioblasts can be efficiently isolated from FSHD muscle biopsies and expanded to an amount of cells necessary to transplant into an adult patient. Proliferating mesoangioblasts from all muscles examined did not differ from controls in terms of morphology, phenotype, proliferation rate, or clonogenicity. However, their differentiation ability into skeletal muscle was variably impaired, and this defect correlated with the overall disease severity and the degree of histopathologic abnormalities of the muscle of origin. A remarkable differentiation defect was observed in mesoangioblasts from all mildly to severely affected FSHD muscles, whereas mesoangioblasts from morphologically normal muscles showed no myogenic differentiation block. Our study could open the way to cell therapy for FSHD patients to limit muscle damage in vivo through the use of autologous mesoangioblasts capable of reaching damaged muscles and engrafting into them, without requiring immune suppression or genetic correction in vitro. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Year:  2007        PMID: 17761758     DOI: 10.1634/stemcells.2007-0465

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  21 in total

1.  Human skeletal muscle cells with a slow adhesion rate after isolation and an enhanced stress resistance improve function of ischemic hearts.

Authors:  Masaho Okada; Thomas R Payne; Lauren Drowley; Ron J Jankowski; Nobuo Momoi; Sarah Beckman; William C W Chen; Bradley B Keller; Kimimasa Tobita; Johnny Huard
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

2.  Vessel-associated stem cells from skeletal muscle: From biology to future uses in cell therapy.

Authors:  Cristina Sancricca; Massimiliano Mirabella; Carla Gliubizzi; Aldobrando Broccolini; Teresa Gidaro; Roberta Morosetti
Journal:  World J Stem Cells       Date:  2010-06-26       Impact factor: 5.326

Review 3.  Mesenchymal Stem Cells in the Musculoskeletal System: From Animal Models to Human Tissue Regeneration?

Authors:  Klemen Čamernik; Ariana Barlič; Matej Drobnič; Janja Marc; Matjaž Jeras; Janja Zupan
Journal:  Stem Cell Rev Rep       Date:  2018-06       Impact factor: 5.739

Review 4.  Stem cell therapy for muscular dystrophies.

Authors:  Stefano Biressi; Antonio Filareto; Thomas A Rando
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

5.  Facioscapulohumeral dystrophy: case report and discussion.

Authors:  Vincenzo Castellano; Joseph Feinberg; Jennifer Michaels
Journal:  HSS J       Date:  2008-07-01

6.  Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats.

Authors:  Darko Bosnakovski; Randy S Daughters; Zhaohui Xu; Jonathan M W Slack; Michael Kyba
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

7.  Analysis of allele-specific RNA transcription in FSHD by RNA-DNA FISH in single myonuclei.

Authors:  Peter S Masny; On Ying A Chan; Jessica C de Greef; Ulla Bengtsson; Melanie Ehrlich; Rabi Tawil; Leslie F Lock; Jane E Hewitt; Jennifer Stocksdale; Jorge H Martin; Silvere M van der Maarel; Sara T Winokur
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

8.  FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy.

Authors:  Ryan D Wuebbles; Meredith L Hanel; Peter L Jones
Journal:  Dis Model Mech       Date:  2009-04-21       Impact factor: 5.758

Review 9.  The origin, molecular regulation and therapeutic potential of myogenic stem cell populations.

Authors:  A Otto; H Collins-Hooper; K Patel
Journal:  J Anat       Date:  2009-08-24       Impact factor: 2.610

10.  Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects.

Authors:  Marietta Barro; Gilles Carnac; Sébastien Flavier; Jacques Mercier; Yegor Vassetzky; Dalila Laoudj-Chenivesse
Journal:  J Cell Mol Med       Date:  2008-05-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.